Immunic, Inc. (IMUX)

1d ago, source: Yahoo Finance

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

1mon ago, source: Morningstar

About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune ...

Immunic (NASDAQ: IMUX)

4d ago, source: The Motley Fool

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.

Immunic secures key patent, boosting MS drug exclusivity and global IP strategy

1mon ago, source: Yahoo Finance

Immunic Inc CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion with news the company has received a Notice of Allowance from the US Patent and Trademark Office for a new patent application ...

Immunic receives US patent covering the composition-of-matter of a specific polymorph of vidofludimus calcium

28d ago, source: Pharmabiz

Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced that it has received ...

Immunic Stock (NASDAQ:IMUX), Analyst Ratings, Price Targets, Predictions

15d ago, source: Benzinga.com

Immunic Inc has a consensus price target of $21, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from Brookline Capital, Wedbush, and Wedbush on ...

Brookline Capital starts Immunic at buy, cites MS drug candidate

14d ago, source: Hosted on MSN

Brookline Capital Markets has initiated coverage of Immunic (NASDAQ:IMUX) with a buy rating, citing the potential of the company’s multiple sclerosis drug candidate IMU-838. The investment firm ...

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)

4d ago, source:

Analysts fell to the sidelines weighing in on Adaptimmune Therapeutics (ADAP – Research Report) and Immunic (IMUX – Research Report) with ...

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

16d ago, source:

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic granted patent for specific polymorph of vidofludimus calcium in US

1mon ago, source: Proactiveinvestors

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...